|
**Overview**: Myeloproliferative Neoplasms Extended Profile**Introduction**: The Myeloproliferative Neoplasms Extended Profile is a diagnostic tool designed to screen for myeloproliferative neoplasms using whole blood or bone marrow samples. In India, MPNs (PV, ET, PMF, CML) affect ~1-3 per 100,000 annually, with driver mutations (JAK2 ~95 percent PV, CALR ~20-25 percent ET/PMF, MPL ~5-10 percent, BCR-ABL in CML) defining diagnosis and therapy. High morbidity from under-testing in rural/low-SES patients with polycythemia, thrombocytosis, or splenomegaly, limited molecular labs, delayed hydroxyurea/ruxolitinib/imatinib leading to thrombosis or progression. Per hematology practices aligned with ICMR and Indian Society of Haematology & Blood Transfusion guidelines, the test employs PCR for JAK2 V617F/Exon 12, CALR, MPL, and BCR-ABL over 1-2 days with high sensitivity, valuable for driver mutation identification and WHO classification. This diagnostic falls under genetic cancer screening and targets patients with suspected MPN or unexplained cytoses, addressing accurate detection to guide cytoreduction or TKI therapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise molecular profiling and reducing MPN complications. Its blood/bone marrow-based approach ensures reliable multi-gene analysis.**Other Names**: MPN Ext Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/hematology/oncology/cytogenetics, compliant with 2025 standards.**Historical Milestone**: Extended driver mutation panel standard; in India, routine in MPN workup.**Purpose**: The test assesses 5 parameters including JAK2 V617F to guide MPN screening, identify drivers, inform therapy.**Test Parameters**: 1. JAK2 V617F, 2. JAK2 Exon 12, 3. CALR, 4. MPL, 5. BCR-ABL.**Pretest Condition**: No fasting required; patients should have cytosis or splenomegaly.**Specimen**: 3 mL whole blood or bone marrow in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve DNA integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for PCR).**Medical History**: Patients should provide details on blood counts, thrombosis.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed MPN including thrombosis, benefits of profiling, and minimal discomfort from sampling.**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive driver mutation confirms MPN subtype, necessitating specialist input.**Specialist Consultation**: Hematologists/oncologists should be consulted for management.**Additional Supporting Tests**: Bone marrow biopsy for confirmation.**Test Limitations**: Detects common drivers; comprehensive approach required.**References**: Indian Journal of Hematology 2024, MPN Studies India 2023. |
